FDA-Approved Ojjaara (Momelotinib) Emerges As Breakthrough Treatment For Myelofibrosis With Anemia

April 12, 2025 — The U.S. Food and Drug Administration (FDA) has approved Ojjaara (momelotinib) as the first and only treatment specifically indicated for myelofibrosis (MF) patients with anemia, marking a significant advancement in managing this rare and debilitating bone marrow cancer.

Developed by GSK, Ojjaara addresses three critical manifestations of the disease—anemia, splenomegaly (enlarged spleen), and constitutional symptoms—offering new hope for patients who previously had limited therapeutic options.

The Ojjaara approval represents an important development in the treatment of myelofibrosis with anemia.

A New Standard Of Care For Myelofibrosis

Myelofibrosis, a rare chronic leukemia, disrupts blood cell production, leading to severe anemia, fatigue, and spleen enlargement.

Approximately 40% of patients present with moderate-to-severe anemia at diagnosis, and most will develop it over time, often requiring frequent blood transfusions and facing a poor prognosis.

Ojjaara’s triple-action mechanism—inhibiting JAK1, JAK2, and ACVR1—sets it apart from existing JAK inhibitors.

By targeting ACVR1, the drug reduces hepcidin levels, a key contributor to anemia in myelofibrosis, while simultaneously alleviating spleen enlargement and systemic symptoms.

This mechanism is a key feature of Ojjaara (momelotinib), the FDA-approved treatment for myelofibrosis with anemia.

Clinical Efficacy Backed By Robust Data

The FDA approval of Ojjaara (momelotinib) was supported by findings from two pivotal trials:

1. MOMENTUM Trial (NCT04173494) – Compared to danazol, Ojjaara demonstrated:
   • 25% of patients achieved ≥50% symptom score reduction (vs. 9% with danazol)7.
   • 30% achieved transfusion independence (vs. 20%)4.
   • 39% saw ≥25% spleen volume reduction (vs. 6%)7.
2. SIMPLIFY-1 Trial (NCT01969838) – In JAK-inhibitor-naïve patients, Ojjaara showed non-inferiority to ruxolitinib in spleen response, with added benefits in anemia management68.

Real-world data further reinforced its efficacy, with 92% of symptomatic patients reporting symptom improvement, including reduced fatigue, abdominal discomfort, and pruritus3.

Ojjaara Safety And Accessibility

While Ojjaara is well-tolerated, common side effects include thrombocytopenia, diarrhea, nausea, and dizziness16. GSK has priced the drug at $26,900 for a 30-tablet supply, but offers patient assistance programs to improve access5.

Following the Ojjaara FDA approval, affordability and access remain important considerations for patients and healthcare systems.

Global Impact And Future Outlook

Following U.S. approval, Ojjaara has also gained Health Canada endorsement and a positive CHMP opinion in the EU, positioning it as a global standard for MF with anemia46.

Experts like Dr. Ruben Mesa (Atrium Health) highlight its potential to “establish a new standard of care” by addressing anemia—a long-unmet need.

With ongoing studies exploring combination therapies, Ojjaara’s role in MF treatment is poised to expand, offering renewed optimism for patients worldwide and further shaping the landscape of FDA-approved treatments for myelofibrosis with anemia.

Sources: FDA, GSK Press Releases, Clinical Trial Data (MOMENTUM, SIMPLIFY-1), Real-World Studies.

About DengYueMed – HK Drug Wholesale Distributor

As a legally compliant drug import and export company, DengYueMed is certified by the pharmacy & poisons board of Hong Kong — you can verify our qualification on their official website.

Our efforts to improve the affordability of Momelotinib drug aim to ensure that more patients can benefit from this important medication.

HK DengYue provides detailed medicine information, transparent pricing, and responsive support to ensure a smooth and reliable buying experience.

Feel free to reach out anytime to discuss your needs or ask questions about the medicine. We welcome you to contact us for a consultation.

FAQ about FDA Approval of Ojjaara (Momelotinib)